Lymphatic filariasis control in Tanga Region, Tanzania: status after eight rounds of mass drug administration

Particle and Fibre Toxicology

William N Kisinza¹  Mwelecele N Malecela²  Anna-Sofie Stensgaard⁵  Erling M Pedersen³  Stephen M Magesa⁴  Yahya A Derua¹  Paul E Simonsen³ 

[1] National Institute for Medical Research, Amani Medical Research Centre, Muheza, Tanzania;National Institute for Medical Research, Dar es Salaam, Tanzania;Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Dyrlægevej 100, Frederiksberg C, 1870, Denmark;RTI International, Global Health Division, Dar es Salaam, Tanzania;Center for Macroecology, Evolution and Climate, Natural History Museum of Denmark, University of Copenhagen, Universitetsparken 15, Copenhagen Ø, 2100, Denmark

关键词: Tanzania;    Vectors;    Circulating filarial antigens;    Microfilariae;    Albendazole;    Ivermectin;    Mass drug administration;    Control;    Wuchereria bancrofti;    Lymphatic filariasis;   

Others  :  1149399
DOI  :  10.1186/s13071-014-0507-5

 received in 2014-08-04, accepted in 2014-10-28,  发布年份 2014

【 摘 要 】

Background

Lymphatic filariasis (LF) control started in Tanga Region of Tanzania in 2004, with annual ivermectin/albendazole mass drug administration (MDA). Since then, the current project has monitored the effect in communities and schools in rural areas of Tanga District. In 2013, after 8 rounds of MDA, spot check surveys were added in the other 7 districts of Tanga Region, to assess the regional LF status.

Methods

LF vector and transmission surveillance, and human cross sectional surveys in communities and schools, continued in Tanga District as previously reported. In each of the other 7 districts, 2¿3 spot check sites were selected and about 200 schoolchildren were examined for circulating filarial antigens (CFA). At 1¿2 of the sites in each district, additional about 200 community volunteers were examined for CFA and chronic LF disease, and the CFA positives were re-examined for microfilariae (mf).

Results

The downward trend in LF transmission and human infection previously reported for Tanga District continued, with prevalences after MDA 8 reaching 15.5% and 3.5% for CFA and mf in communities (decrease by 75.5% and 89.6% from baseline) and 2.3% for CFA in schoolchildren (decrease by 90.9% from baseline). Surprisingly, the prevalence of chronic LF morbidity after MDA 8 was less than half of baseline records. No infective vector mosquitoes were detected after MDA 7. Spot checks in the other districts after MDA 8 showed relatively high LF burdens in the coastal districts. LF burdens gradually decreased when moving to districts further inland and with higher altitudes.

Conclusion

LF was still widespread in many parts of Tanga Region after MDA 8, in particular in the coastal areas. This calls for intensified control, which should include increased MDA treatment coverage, strengthening of bed net usage, and more male focus in LF health information dissemination. The low LF burdens observed in some inland districts suggest that MDA in these could be stepped down to provide more resources for upscale of control in the coastal areas. Monitoring should continue to guide the programme to ensure that the current major achievements will ultimately lead to successful LF elimination.

【 授权许可】

   
2014 Simonsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Simonsen PE, Fischer PU, Hoerauf A, Weil GJ: The Filariases. In Manson¿s Tropical Diseases. 23rd edition. Edited by Farrar J, Hotez PJ, Junghanss T, Kang G, Lalloo D, White NJ. Elsevier Saunders, London; 2014:737-765.
• [2]WHO: Lymphatic Filariasis: Managing Morbidity and Preventing Disability. Geneva: World Health Organization; 2013.
• [3]Ottesen EA: Lymphatic filariasis: treatment, control and elimination. Adv Parasitol 2006, 61:395-441.
• [4]Global Programme to Eliminate Lymphatic Filariasis. Progress report 2000¿2009 and strategic plan 2010¿2020. World Health Organization, Geneva; 2010.
• [5]WHO: Monitoring and Epidemiological Assessment of Mass Drug Administration in the Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes. Geneva: World Health Organization; 2011.
• [6]Hotez PJ, Kamath A: Neglected tropical diseases in Sub-Saharan Africa: review of their prevalence, distribution and disease burden. PLoS Negl Trop Dis 2009, 3:e412.
• [7]Malecela MN, Lazarus W, Mwingira U, Mwakitalu E, Makene C, Kabali C, Mackenzie C: Eliminating LF: a progress report from Tanzania. J Lymphol 2009, 4:10-12.
• [8]Minjas JN, Kihamia CN: Bancroftian filariasis. In Health and disease in Tanzania. Edited by Mwaluko GMP, Kilama WL, Mandara MP, Murru M, Macpherson CNL. Harper Collins Academic, London; 1991:159-176.
• [9]McMahon JE, Magayuka SA, Kolstrup N, Mosha FW, Bushrod FM, Abaru DE, Bryan JH: Studies on the transmission and prevalence of bancroftian filariasis in four coastal villages of Tanzania. Ann Trop Med Parasitol 1981, 75:415-431.
• [10]Meyrowitsch DW, Simonsen PE, Makunde WH: Bancroftian filariasis: analysis of infection and disease in five endemic communities of north-eastern Tanzania. Ann Trop Med Parasitol 1995, 89:653-663.
• [11]Simonsen PE, Meyrowitsch DW, Makunde WH, Magnussen P: Bancrotian filariasis: The pattern of microfilaraemia and clinical manifestations in three endemic communities of Northeastern Tanzania. Acta Trop 1995, 60:179-187.
• [12]Simonsen PE, Meyrowitsch DW, Jaoko WG, Malecela MN, Mukoko D, Pedersen EM, Ouma JH, Rwegoshora RT, Masese NN, Magnussen P, Estambale BBA, Michael E: Bancroftian filariasis infection, disease, and specific antibody response patterns in a high and a low endemicity community in East Africa. Am J Trop Med Hyg 2002, 66:550-559.
• [13]Rwegoshora RT, Pedersen EM, Mukoko DA, Meyrowitsch DW, Masese N, Malecela-Lazaro MN, Ouma JH, Michael E, Simonsen PE: Bancroftian filariasis: patterns of vector abundance and transmission in two East African communities with different levels of endemicity. Ann Trop Med Parasitol 2005, 99:253-265.
• [14]Community-directed interventions for priority health problems in Africa: results of a multi-country study Bull Wld Health Org 2010, 88:509-518.
• [15]Kisoka WL, Tersbøl BP, Meyrowitsch DW, Simonsen PE, Mushi DL: Community members¿ perceptions of mass drug administration for control of lymphatic filariasis in rural and urban Tanzania.J Biosocial Sci 2014, In press.
• [16]Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA, Magesa SM: Lymphatic filariasis control in Tanzania: Effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission. PLoS Negl Trop Dis 2010, 4:e696.
• [17]Simonsen PE, Magesa SM, Derua YA, Rwegoshora RT, Malecela MN, Pedersen EM: Monitoring lymphatic filariasis control in Tanzania: effect of repeated mass drug administration on circulating filarial antigen prevalence in young schoolchildren. Int Health 2011, 3:182-187.
• [18]Simonsen PE, Derua YA, Kisinza WN, Magesa SM, Malecela MN, Pedersen EM: Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission. BMC Infect Dis 2013, 13:335. BioMed Central Full Text
• [19]McMahon JE, Marshall TF, Vaughan JP, Abaru DE: Bancroftian filariasis: a comparison of microfilariae counting techniques using counting chamber, standard slide and membrane (nuclepore) filtration. Ann Trop Med Parasitol 1979, 73:457-464.
• [20]Pilz J, Spöck G: Why do we need and how should we implement Bayesian kriging methods? Stoch Environ Res Risk Assess 2007, 22:621-632.
• [21]Simonsen PE, Niemann L, Meyrowitsch DW: Wuchereria bancrofti in Tanzania: microfilarial periodicity and effect of blood sampling time on microfilarial intensities. Trop Med Int Health 1997, 2:153-158.
• [22]Chu BK, Deming M, Biritwum NK, Dorkenoo AM, El-Setouhy M, Fischer PU, Gass K, de Pena MG, Mercado-Hernandez L, Kyelem D, Lammie PJ, Flueckiger RM, Mwingira UJ, Noordin R, Owusu IO, Ottesen EA, Pavluck A, Pilotte N, Rao BU, Samarasekera D, Schmaedick MA, Settinayake S, Simonsen PE, Supali T, Taleo F, Torres M, Weil GJ, Won KY: Transmission Assessment Surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop Dis 2013, 7:e2584.
• [23]Meyrowitsch DW, Pedersen EM, Alifrangis M, Scheike TH, Malecela MN, Magesa SM, Derua YA, Rwegoshora RT, Michael E, Simonsen PE: Is the current decline in malaria burden in sub-Saharan Africa due to a decrease in vector population? Malar J 2011, 10:188. BioMed Central Full Text
• [24]Derua YA, Alifrangis M, Hosea KM, Meyrowitsch DW, Magesa SM, Pedersen EM, Simonsen PE: Change in composition of the Anopheles gambiae complex and its possible implications for the transmission of malaria and lymphatic filariasis in north-eastern Tanzania. Malar J 2012, 11:188. BioMed Central Full Text
• [25]Ramzy RMR, El Setouhy M, Helmy H, Ahmed ES, Elaziz KMA, Farid HA, Shannon WD, Weil GJ: Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: A comprehensive assessment. Lancet 2006, 367:992-999.
• [26]Liang JL, King JD, Ichimori K, Handzel T, Pa¿au M, Lammie PJ: Impact of five annual rounds of mass drug administration with diethylcarbamazine and albendazole on Wuchereria bancrofti infection in American Samoa. Am J Trop Med Hyg 2008, 78:924-928.
• [27]Weil GJ, Kastens W, Susapu M, Laney SJ, Williams SA, King CL, Kazura JW, Bockarie MJ: The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis 2008, 2:e344.
• [28]Ramaiah KD, Vanamail P, Yuvaraj J, Das PK: Effect of annual mass administration of diethylbarbamazine and albendazole on bancroftian filariasis in five villages in South India. Trans R Soc Trop Med Hyg 2011, 105:431-437.
• [29]Oscar R, Lemoine JF, Direny AN, Desir L, de Rochars VEMB, Poirier MJP, Varghese A, Obidegwu I, Lammie PJ, Streit TG, Milord MD: Haiti National Program for the Elimination of Lymphatic Filariasis ¿ A model of success in the face of adversity. PLoS Negl Trop Dis 2014, 8:e2915.
• [30]Sodahlon YK, Dorkenoo AM, Morgah K, Nabiliou K, Agbo K, Miller R, Datagni M, Seim A, Mathieu E: A success story: Togo is moving toward becoming the first sub-Saharan African nation to eliminate lymphatic filariasis through mass drug administration and countrywide morbidity alleviation. PLoS Negl Trop Dis 2013, 7:e2080.
• [31]Budge PJ, Dorkenoo AM, Sodahlon YK, Fasuyi OB, Mathieu E: Ongoing surveillance for lymphatic filariasis in Togo: assessment of alternatives and nationwide reassessment of transmission status. Am J Trop Med Hyg 2014, 90:89-95.
• [32]Koroma JB, Sesay S, Sonnie M, Hodges MH, Sahr F, Zhang Y, Bockarie MJ: Impact of three rounds of mass drug administration on lymphatic filariasis in areas previously treated for onchocerciasis in Sierre Leone. PLoS Negl Trop Dis 2013, 7:e2273.
• [33]Richards FO, Eigege A, Miri ES, Kal A, Umaru J, Pam D, Rakers LJ, Sambo Y, Danboyi J, Ibrahim B, Adelamo SE, Ogah G, Goshit D, Oyenekan OK, Mathieu E, Withers PC, Saka YA, Jiya J, Hopkins DR: Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria. PLoS Negl Trop Dis 2011, 5:e1346.
• [34]King JD, Eigege A, Umaru J, Jip N, Miri E, Jiya J, Alphonsus KM, Sambo Y, Graves P, Richards F: Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria. Am J Trop Med Hyg 2012, 87:272-280.
• [35]Mohammed KA, Molyneux DH, Albonico M, Rio F: Progress towards eliminating lymphatic filariasis in Zanzibar: a model programme. Trends Parasitol 2006, 22:340-344.
• [36]Pedersen EM, Stolk WA, Laney SJ, Michael E: The role of monitoring mosquito infection in the Global Programme to Eliminate Lymphatic Filariasis. Trends Parasitol 2009, 25:319-327.
• [37]Irish SR, Moore SJ, Derua YA, Bruce J, Cameron MM: Evaluation of gravid traps for the collection of Culex quinquefasciatus, a vector of lymphatic filariasis in Tanzania. Trans R Soc Trop Med Hyg 2013, 107:15-22.
• [38]Addiss DG, Brady MA: Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filar J 2007, 6:2. BioMed Central Full Text
• [39]Bernhard P, Magnussen P, Lemnge MM: A randomized, double-blind, placebo-controlled study with diethylcarbamazine for the treatment of hydrocele in an area of Tanzania endemic for lymphatic filariasis. Trans R Soc Trop Med Hyg 2001, 95:534-536.
• [40]Eddy BA, Blackstock AJ, Williamson JM, Addiss DG, Streit TG, de Rochars VMB, Fox LM: A longitudinal analysis of the effect of mass drug administration on acute inflammatory episodes and disease progression in lymphedema patients in Leogane, Haiti. Am J Trop Med Hyg 2014, 90:80-88.
• [41]Kisoka WL, Simonsen PE, Malecela MN, Tersboel BP, Mushi DL, Meyrowitsch DW: Factors influencing drug uptake during mass drug administration for control of lymphatic filariasis in rural and urban Tanzania.PLoS One 2014, 10:e109316
• [42]Krentel A, Fischer PU, Weil GJ: A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis 2013, 7:e2447.
• [43]Jordan P: Filariasis in the Eastern, Tanga and Northern Provinces of Tanganyika. East Afr Med J 1956, 33:225-233.
• [44]Kyelem D, Sanou S, Boatin B, Medlock J, Coulibaly S, Molyneux DH: Impact of long-term ivermectin (Mectizan®) on Wuchereria bancrofti and Mansonella perstans infections in Burkina Faso: strategic and policy implications. Ann Trop Med Parasitol 2003, 97:827-838.
• [45]Keylem D, Medlock J, Sanou S, Bonkoungou M, Boatin B, Molyneux DH: Short communication: Impact of long-term (14 years) bi-annual ivermectin treatment on Wuchereria bancrofti microfilaraemia. Trop Med Int Health 2005, 10:1002-1004.
• [46]Mwakitalu ME, Malecela MN, Pedersen EM, Mosha FW, Simonsen PE: Urban lymphatic filariasis in the city of Tanga, Tanzania, after seven rounds of mass drug administration. Acta Trop 2013, 128:692-700.
• [47]Njenga SM, Mwandawiro CS, Wamae CN, Mukoko DA, Omar AA, Shimada M, Bockarie MJ, Molyneux DH: Sustained reduction in prevalence of lymphatic filariasis infection in spite of missed rounds of mass drug administration in an area under mosquito nets for malaria control. Parasit Vectors 2011, 4:90. BioMed Central Full Text
• [48]Kelly-Hope LA, Molyneux DH, Bockarie MJ: Can malaria vector control accelerate the interruption of lymphatic filariasis transmission in Africa; capturing a window of opportunity? Parasit Vectors 2013, 6:39. BioMed Central Full Text
• [49]Reimer LJ, Thomsen EK, Tssch DJ, Henry-Halldin CN, Zimmerman PA, Baea ME, Dagoro H, Sasapu M, Hetzel MW, Bockarie MJ, Michael E, Siba PM, Kazura JW: Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med 2013, 369:745-753.
• [50]Richards FO, Emukah E, Graves PM, Nkwocha O, Nwankwo L, Rakers L, Mosher A, Patterson A, Ozaki M, Nwoke BEB, Ukaga CN, Njoku C, Nwodu K, Obasi A, Miri ES: Community-wide distribution of long-lasting insecticidal nets can halt transmission of lymphatic filariasis in Southeastern Nigeria. Am J Trop Med Hyg 2013, 89:578-587.